Celgene sales miss, profits double; Opdivo closes in on first-line melanoma use;

@FiercePharma: IDEXX misses earnings target, dampens 2015 forecast. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: GSK licks Nicorette manufacturing problems; 'Minis' are back. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: After topping Q1 estimates, Valeant hikes guidance on Salix buy. ICYMI yesterday | Follow @CarlyHFierce

> Celgene's ($CELG) profit more than doubled as its top-selling blood cancer drug Revlimid continued its growth march in the U.S., but overall sales fell short of analyst estimates. Story | Report

> Bristol-Myers Squibb ($BMY) said the FDA accepted its application for broader use of its cancer drug Opdivo, in patients newly diagnosed with melanoma. Release

> Shire ($SHPG) has appointed interim CFO Jeff Poulton as its CFO, and he'll also join the company's board of directors. Release

> Belgian drugmaker UCB posted double-digit sales growth in the first quarter, thanks to strong Cimzia performance and a boost in orders for its off-patent epilepsy med Keppra. Report

> Kythera won FDA approval for its injection designed to combat double chin, Kybella, and plans to launch the drug during the second half of this year. Report

> Bristol-Myers Squibb priced a European debt offering worth 1.15 billion euros, with two tranches due in 2025 and 2035. Report

Medical Device News

@FierceMedDev: ICYMI: Kleiner Perkins backs Rapid Micro Biosystems in $25M for microbial detection in quality control. Report | Follow @FierceMedDev

@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Researchers Yale used gene editing tech to fix a mutation commonly linked to cystic fibrosis. FierceBiotechResearch article | Follow @EmilyWFierce

> Boston Sci courts hospitals with a pair of deals to boost patient outcomes and lower costs. Story

> Harvard point-of-care handheld cancer diagnostic spinoff WaveGuide raises $13.9M. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Kythera bags FDA approval for its double-chin-shrinking shot. Report | Follow @FierceBiotech

@JohnCFierce: To restate: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. (Once owned a VTec) | Follow @JohnCFierce

@DamianFierce: Wasn't it odd that $SNTA said Whitaker's new job "allows her to be located closer to her family" in its PR? | Follow @DamianFierce

> With Teva out, OncoGenex shrinks its PhIII lung cancer study. Article

> Sanofi-backed MyoKardia nabs a $46M round for cardio pipeline construction. Report

CRO News

> WuXi's CEO moves to take the CRO private. News

> Icon dampens its outlook despite a strong quarter. Report

> Quintiles scales back its 2015 projections after a mixed quarter. More

> Charles River ticks up its revenue amid a shift in focus. Story

> INC swings to profit and dials up its revenue expectations. Article

Vaccines News

> As California measles cases mounted, so did Merck measles vaccine sales. Item

> 80% leap for Pfizer's U.S. Prevnar sales trounces Q1 estimates. Report

> GSK's shingles candidate more effective than Merck's Zostavax in older adults, study says. Story

> Amgen wins FDA panel nod for T-Vec in melanoma. News

> Final trial results show GSK malaria vaccine's efficacy wanes over time. Article

Pharma Manufacturing News

> FDA wants manufacturers to test APIs in hospital antiseptics. More

> AmerisourceBergen keeps up momentum gained from Walgreens deal. News

> Drug shortages become issue in Teva and Mylan hook-up. Article

> Attix Pharmaceuticals recalls hundreds of APIs from the U.S. News

> Hospira's Rocky Mount warning letter lifted; Pfizer benefits. Story

Pharma Asia News

> India works with Hilleman to help industry avoid waste in vaccines stockpile. Report

> China on standardized quality push for traditional medicines. Story

> Singapore's Temasek piles into Indian pharma to the tune of $567.7M. More

> China devices market set to soar by 2020 as GDP overtakes U.S., report says. Item

> Hospital drug sales noted by Premier Li in China reform push. Article

And Finally... Why do some people get fitter than others? Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.